Abridge, the leading generative AI platform for clinical conversations, has raised a $250 million Series D investment, coinciding with the milestone of surpassing 100 deployments at some of the largest and most complex health systems in the United States.
Read also – Funding Wrap of the Week | American Startups Funding Roundup | February 10 – February 14
The Series D investment, co-led by Elad Gil and IVP, includes contributions from Bessemer Venture Partners, California Health Care Foundation, CapitalG, CVS Health Ventures, K. Ventures, Lightspeed Venture Partners, NVentures (NVIDIA’s venture capital arm), Redpoint Ventures, Spark Capital, and SV Angel.
Read also – Junevity Raises $10Mn in Seed Funding
The investment will fuel additional development of AI capabilities and commercial growth to support broader applications.
“We are excited about the potential of Abridge’s technology to enhance Inova’s clinical documentation across our care sites,” said Matt Kull, Executive Vice President, Chief Information and Digital Officer, Inova. “The quality of specialty-specific notes and Abridge’s responsiveness to clinician feedback with rigorously tested enhancements stood out to us. Learning more about the innovation behind the scenes—ensuring notes are both clinically useful and billing compliant—along with the demonstrated ROI at other institutions has been compelling as we explore this solution.”
Abridge, recently named Best in KLAS for the Ambient AI segment, has also introduced a new Contextual Reasoning Engine—an AI architecture that produces more clinically useful and billable notes at the point of care. Today, healthcare systems are plagued by incomplete clinical notes that delay billing processes, resulting in the loss of countless hours spent improving documents, often weeks or months after a patient visit. Generating comprehensive, billable notes that support appropriate claims at the point of care creates administrative efficiencies, reducing costs and freeing doctors to focus more on patient care.
“The Abridge Contextual Reasoning Engine helps us concentrate more value into our core documentation offering, integrating system and revenue cycle requirements into a sophisticated and orchestrated system of AI models,” said Dr. Shiv Rao, Abridge CEO and Founder. “We aspire to serve our health system partners for the decades to come. This investment supports that aspiration, as well as the core research and development that differentiates our approach.”
Abridge is now implemented at a diverse set of more than 100 of the largest and most complex healthcare systems in the U.S. From rural systems to children’s hospitals to leading academic systems and nationally recognized cancer centers, Abridge is used by clinicians of every specialty across all care settings, and in over 28 languages.
About Abridge
Abridge was founded in 2018 to power deeper understanding in healthcare. The enterprise-grade AI platform transforms medical conversations into clinically useful and billable documentation at the point of care, reducing administrative burden and clinician burnout while improving patient experience. With deep EHR integration, support for 28+ languages, and 50+ specialties, Abridge is used across a wide range of care settings, including outpatient, emergency department, and inpatient.
Abridge’s enterprise-grade AI platform is purpose-built for healthcare. Supported by Linked Evidence, Abridge is the only solution that maps AI-generated summaries to source data, helping clinicians quickly trust and verify the output. As a pioneer in generative AI for healthcare, Abridge is setting the industry standard for the responsible deployment of AI across health systems.
Abridge was recently awarded Best in KLAS for Ambient AI segment in addition to other accolades, including TIME Best Inventions of 2024, 2024 Forbes AI 50 List, and Fortune’s 2024 AI 50 Innovators.
